Dtsch Med Wochenschr 2016; 141(07): 490-492
DOI: 10.1055/s-0042-100099
Klinischer Fortschritt
Rheumatologie
© Georg Thieme Verlag KG Stuttgart · New York

Polymyalgia rheumatica

Polymyalgia rheumatica – what’s new?
Wolfgang A. Schmidt
1   Immanuel Krankenhaus Berlin, Rheumaklinik Berlin-Buch
› Author Affiliations
Further Information

Publication History

Publication Date:
31 March 2016 (online)

    Permissions and Reprints

Zusammenfassung

Mittels Ultraschall, MRT oder PET-CT lassen sich zusätzlich typische entzündliche Veränderungen im Schulter- und Beckengürtelbereich nachweisen, mittels MRT und PET-CT sogar paravertebral. Neue Klassifikationskriterien beinhalten Alter ≥ 50 Jahre, CRP- und / oder BSG-Erhöhung, Schultergürtelschmerz sowie zwei Algorithmen mit oder ohne Ultraschall. Letzter Algorithmus hat eine höhere Spezifität bei gleicher Sensitivität. Entsprechend neuen Therapieempfehlungen soll die Diagnose möglichst definitiv gestellt werden. Basis -Laboruntersuchungen und Komorbiditäten müssen berücksichtigt werden. Zunächst wird 12,5–25 mg / d Prednisonäquivalent verordnet und dann die Dosis auf 10 mg / d innerhalb von 4–8 Wochen reduziert, gefolgt von einer 4-wöchentlichen Reduktion um je 1 mg. Bei Risiken und Begleiterkrankungen kann zusätzlich Methotrexat verordnet werden. Verlaufskontrollen sollen innerhalb des 1. Jahres alle 4–8 Wochen erfolgen.

Abstract

Ultrasound, MRI and PET-CT reveal a typical anatomical distribution of inflammation in the shoulder and pelvic girdle. MRI and PET-CT may additionally show inflammation along the spine. New classification criteria include age ≥ 50 years, elevated CRP and / or ESR, and shoulder girdle pain as well as two alternative algorithms with or without ultrasound. The algorithm with ultrasound is more specific but equally sensitive than the other algorithm. According to new recommendations on management diagnosis should be definitely established. Lab tests need to be considered as well as comorbidities. A starting dose of 12.5–25 mg / d prednisone – equivalent is recommended, followed by a dose reduction to 10 mg / d within 4–8 weeks. Afterwards the dose should be reduced by 1 mg every 4 weeks. Methotrexate might be added in patients with significant risks and comorbidities. Follow-up visits should occur every 4–8 weeks during the first year.

Schlüsselwörter

Polymyalgia rheumatica - Riesenzellarteriitis - Klassifikationskriterien - Empfehlungen - Ultraschall

Keywords

Polymyalgia rheumatica - giant cell arteritis - classification criteria - recommendations - ultrasonography
 

  • Literatur

  • 1 Schmidt WA. Polymyalgia rheumatica. Z Rheumatol 2013; 72: 59-65
    CrossrefGoogle Scholar
  • 2 Mackie SL, Koduri G, Hill CL et al. Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review. RMD Open 2015; 1: e000100
    CrossrefGoogle Scholar
  • 3 Camellino D, Paparo F, Morbelli S et al. Interspinous bursitis is common in polymyalgia rheumatica, but is not associated with spinal pain. Arthritis Res Ther 2014; 16: 492
    CrossrefGoogle Scholar
  • 4 Schmidt WA. Imaging in vasculitis. Best Pract Res Clin Rheumatol 2013; 27: 107-118
    CrossrefGoogle Scholar
  • 5 Dasgupta B, Cimmino MA, Maradit-Kremers H et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism / American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012; 71: 484-492
    CrossrefGoogle Scholar
  • 6 Macchioni P, Boiardi L, Catanoso M et al. Performance of the new 2012 EULAR / ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. Ann Rheum Dis 2014; 73: 1190-1193
    CrossrefGoogle Scholar
  • 7 Dejaco C, Singh Y, Perel P et al. Current evidence for therapeutic interventions and prognostic factors in Polymyalgia Rheumatica. Ann Rheum Dis 2015; 74: 1808-1817
    CrossrefGoogle Scholar
  • 8 Dejaco C, Singh YP, Perel P et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism / American College of Rheumatology collaborative initiative. Ann Rheum Dis 2015; 74: 1799-1807
    CrossrefGoogle Scholar
  • 9 Schmidt WA. Polymyalgia rheumatica (PMR) und Riesenzellarteriitis (Arteriitis temporalis). In: Jung N, Mayet WJ, Mertens PR et al., Hrsg. Rationelle Diagnostik und Therapie in der Inneren Medizin. 42. Lieferung, München: Elsevier; 2015
    Google Scholar
  • 10 Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int 2013; 2013: 120 638
    Google Scholar
  • 11 Izumi K, Kuda H, Ushikubo M et al. Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases. RMD Open 2015; 1: e000162
    CrossrefGoogle Scholar